Global /United States /Healthcare /Drug Manufacturers - General /ARCT

Arcturus Therapeutics Holdings Inc.

ARCT

• NASDAQ: ARCT • Delayed

8.40USD -5.3%

As of 13 June 2026, Arcturus Therapeutics Holdings Inc. has a market cap of $238.75M USD, ranking #19985 globally and #3290 in the United States. It ranks #1798 in the Healthcare sector, and #655 in the Drug Manufacturers - General industry.

Global Rank

19985

Country Rank

3290

Sector Rank

1798

Industry Rank

655

Key Stats

Market Cap

$238.75MUSD

Enterprise Value

$35.69MUSD

Revenue (TTM)

$82.03MUSD

EBITDA (TTM)

-$73.24MUSD

Net Income (TTM)

-$65.78MUSD

EBITDA Margin

-89%

Profit Margin

-80%

PS Ratio

2.9

PB Ratio

1.2

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Joseph Payne open_in_new

Employees

111

Founded

2013

Website

arcturusrx.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-5.3%	-2.8%	24%	14%	-15%	37%	-35%	-69%	-78%

News

ARCT Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	ARCT Arcturus Therapeutics Holdings Inc ISIN: US03969T1097 Shares Out.: Shares Outstanding: 28.423M¹ Shares Float: 26.047M² TV: TradingView: NASDAQ: ARCT SA: Stock Analysis: NASDAQ: ARCT YF: Yahoo Finance: ARCT GF: Google Finance: NASDAQ: ARCT NQ: NASDAQ: ARCT BA: Barron's: ARCT MS: Morningstar: XNAS: ARCT	8.40 USD	TV: TradingView: NASDAQ: ARCT SA: Stock Analysis: NASDAQ: ARCT YF: Yahoo Finance: ARCT GF: Google Finance: NASDAQ: ARCT NQ: NASDAQ: ARCT BA: Barron's: ARCT MS: Morningstar: XNAS: ARCT

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Similar Companies

Industry: Drug Manufacturers - General (United States)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 319K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 229K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 151K%	97.4	United States
Merck & Co., Inc. NYSE: MRK	$274.03B 115K%	15.1	United States
Pfizer Inc. NYSE: PFE	$149.38B 62K%	19.5	United States
Bristol-Myers Squibb Co. NYSE: BMY	$117.58B 49K%	16.8	United States

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 135K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 121K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 115K%	20.5	Switzerland
Novo Nordisk A/S CPH: NOVO-B	$181.82B 1.18T DKK 76K%	11.5	Denmark
Sanofi EPA: SAN	$110.1B 95.26B EUR 46K%	19.9	France
GSK plc LSE: GSK	$108.46B 80.96B GBP 45K%	14.6	United Kingdom

chevron_leftBack